FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel DeAngelo

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Mutation

Phenomena

Recurrence

Procedures

Co-author Network

Publications

TOP 3
Jon C Aster; Daniel J DeAngelo
Resistance revealed in acute lymphoblastic leukemia.
Eyal C Attar; Clara D Bloomfield; William Blum; Daniel J DeAngelo; Jeffrey L Johnson; Jonathan E Kolitz; Philip C Amrein; Gerard Lozanski; Guido Marcucci; Barry Moser; Bayard L Powell; Richard M Stone; Peter Voorhees; Martha Wadleigh; Eunice S Wang; Richard A Larson
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Joseph C Alvarnas; Patricia Aoun; Karen Kuhn Ballen; Naresh Bellam; William Blum; Michael W Boyer; Patrick Brown; Hetty Carraway; Peter F. Coccia; Steven E Coutre; Jennifer Cultrera; Lloyd E Damon; Daniel J DeAngelo; Dan Douer; Haydar Frangoul; Olga Frankfurt; Salil Goorha; Kristina M Gregory; Michael Millenson; Maoko Naganuma; Susan O'Brien; Stephen H Petersdorf; Arati V Rao; Stephanie Terezakis; Geoffrey Uy; Meir Wetzler; Andrew D Zelenetz
Acute lymphoblastic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel DeAngelo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jon C Aster; Daniel J DeAngelo
Resistance revealed in acute lymphoblastic leukemia.
Nature medicine 2013;19(3):264-5.
2013: Eyal C Attar; Clara D Bloomfield; William Blum; Daniel J DeAngelo; Jeffrey L Johnson; Jonathan E Kolitz; Philip C Amrein; Gerard Lozanski; Guido Marcucci; Barry Moser; Bayard L Powell; Richard M Stone; Peter Voorhees; Martha Wadleigh; Eunice S Wang; Richard A Larson
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(7):923-9.
2012: Joseph C Alvarnas; Patricia Aoun; Karen Kuhn Ballen; Naresh Bellam; William Blum; Michael W Boyer; Patrick Brown; Hetty Carraway; Peter F. Coccia; Steven E Coutre; Jennifer Cultrera; Lloyd E Damon; Daniel J DeAngelo; Dan Douer; Haydar Frangoul; Olga Frankfurt; Salil Goorha; Kristina M Gregory; Michael Millenson; Maoko Naganuma; Susan O'Brien; Stephen H Petersdorf; Arati V Rao; Stephanie Terezakis; Geoffrey Uy; Meir Wetzler; Andrew D Zelenetz
Acute lymphoblastic leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(7):858-914.
2012: Versha Banerji; Kwan T Chow; Daniel J DeAngelo; Stacey M Frumm; Ilene Galinsky; Cynthia K Hahn; William C Hahn; Haig Inguilizian; Rose M Kakoza; Andrew L Kung; Loretta S Li; Kenneth N Ross; Linda Ross; Giovanni Roti; Anna C Schinzel; Gabriela Alexe; Jon C Aster; Richard M Stone; Nicola Tolliday; Kimberly Stegmaier
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.
The Journal of clinical investigation 2012;122(3):935-47.
2011: Harshabad Singh; Richard M Stone; Martha Wadleigh; Lillian L Werner; Karen K Ballen; Daniel J DeAngelo; Edward A Fox; Ilene Galinsky; Donna S Neuberg; Philip C Amrein; Salma Asali; Eyal C Attar
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
Leukemia research 2011;35(12):1611-5.
2011: Triona Ni Chonghaile; Paul Richardson; Jeremy A Ryan; Stephen E Sallan; Kristopher A Sarosiek; Lewis Silverman; Richard Stone; Yu-Tzu Tai; Anupama Tammareddi; Thanh-Trang Vo; Kenneth C Anderson; Daniel Ruben Carrasco; Daniel J DeAngelo; Jing Deng; Ronny Drapkin; Michelle S Hirsch; Ursula A Matulonis; David J McConkey; Constantine S Mitsiades; Victoria Del Gaizo Moore; Anthony Letai
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science (New York, N.Y.) 2011;334(6059):1129-33.
2011: Marcella M Alsan; Daniel J DeAngelo; Sarah P Hammond; Nicolas C Issa; Danny A Milner; Lindsey R Baden
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2011;11(4):375-7.
2010: Nitin Roper; Daniel J DeAngelo; Frank Kuo; Paola Dal Cin; Irene M Ghobrial; Jon C Aster
An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma.
American journal of hematology 2010;85(12):944-6.
2010: Thomas Fischer; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Elihu Estey; Carlo Lanza; Edward Fox; Gerhard Ehninger; Eric J Feldman; Gary J Schiller; Virginia Klimek; Stephen D Nimer; D Gary Gilliland; Catherine Dutreix; Alice Huntsman-Labed; Jodi Virkus; Francis J Giles
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):4339-45.
2010: Sarah P Hammond; Francisco M Marty; Julie M Bryar; Daniel J DeAngelo; Lindsey R Baden
Invasive fungal disease in patients treated for newly diagnosed acute leukemia.
American journal of hematology 2010;85(9):695-9.
2010: Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(8):1037-69.
2010: Daniel J DeAngelo; Eyal C Attar
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Leukemia & lymphoma 2010;51(3):363-75.
2010: Gary J Schiller; Susan M O'Brien; Arnaud Pigneux; Daniel J DeAngelo; Norbert Vey; Jonathan Kell; Scott Solomon; Robert K Stuart; Verena Karsten; Ann L Cahill; Maher X Albitar; Francis Giles
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):815-21.
2010: Akinori Yoda; Yuka Yoda; Sabina Chiaretti; Michal Bar-Natan; Kartik Mani; Scott J Rodig; Nathan West; Yun Xiao; Jennifer R Brown; Constantine Mitsiades; Martin Sattler; Jeffery L Kutok; Daniel J DeAngelo; Martha Wadleigh; Alfonso Piciocchi; Paola Dal Cin; James E Bradner; James D Griffin; Kenneth C Anderson; Richard M Stone; Jerome Ritz; Robin Foà; Jon C Aster; David A Frank; David M Weinstock
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(1):252-7.
2009: Francis Giles; Norbert Vey; Daniel J DeAngelo; Karen Seiter; Wendy Stock; Robert Stuart; Darinka Boskovic; Arnaud Pigneux; Martin S Tallman; Joseph Brandwein; Jonathan Kell; Tadeusz Robak; Peter Staib; Xavier Thomas; Ann Cahill; Maher Albitar; Susan O'Brien
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood 2009;114(19):4027-33.
2009: Cynthia K Hahn; Jacob E Berchuck; Kenneth N Ross; Rose M Kakoza; Karl Clauser; Anna C Schinzel; Linda Ross; Ilene Galinsky; Tina N Davis; Serena J Silver; David E Root; Richard M Stone; Daniel J DeAngelo; Martin Carroll; William C Hahn; Steven A Carr; Todd R Golub; Andrew L Kung; Kimberly Stegmaier
Proteomic and genetic approaches identify Syk as an AML target.
Cancer cell 2009;16(4):281-94.
2009: Daniel J DeAngelo
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Hematology/oncology clinics of North America 2009;23(5):1121-35, vii-viii.
2009: Richard M Stone; Daniel J DeAngelo
Screens, iron, and leukemia.
Blood 2009;114(14):2857-8.
2009: Ivan Borrello; Hyam I Levitsky; Wendy Stock; Dorie Sher; LU QIN; Daniel J DeAngelo; Edwin P Alyea; Richard M Stone; Lloyd E Damon; Charles A Linker; Daniel J Maslyar; Kristen M Hege
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
Blood 2009;114(9):1736-45.
2009: Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
A forgotten cause of kidney injury in chronic myelomonocytic leukemia.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2009;54(1):159-64.
2009: Steven M Corsello; Giovanni Roti; Kenneth N Ross; Kwan T Chow; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Andrew L Kung; Todd R Golub; Kimberly Stegmaier
Identification of AML1-ETO modulators by chemical genomics.
Blood 2009;113(24):6193-205.
2009: John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
JAMA : the journal of the American Medical Association 2009;301(22):2349-61.
2009: Richard M Stone; Kathleen A Donohue; Wendy Stock; Vera Hars; Charles A Linker; Thomas C Shea; Daniel J DeAngelo; Guido Marcucci; Clara D Bloomfield; Richard A Larson
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Cancer chemotherapy and pharmacology 2009;63(5):859-64.
2008: Richard M Stone; Daniel J DeAngelo; Anna Janosova; Ilene Galinsky; Christine Canning; Jerome Ritz; Robert J Soiffer
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
American journal of hematology 2008;83(10):771-7.
2008: Jennifer L Poitras; Paola Dal Cin; Jon C Aster; Daniel J DeAngelo; Cynthia C Morton
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
Genes, chromosomes & cancer 2008;47(10):884-9.
2008: Santosh kesari; Serra Akar; Ali Saad; Jan Drappatz; Igor J Koralnik; Daniel J DeAngelo
Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(22):3804-7.
2008: Daniel J DeAngelo; Richard M Stone
New agents for the treatment of patients with acute lymphoblastic leukemia.
Current hematologic malignancy reports 2008;3(3):135-43.
2008: Santosh kesari; Jan Drappatz; Serra Akar; Jo-Anne Vergilio; Patrick Y Wen; Robert J Soiffer; Richard M Stone; Daniel J DeAngelo
Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3279-81.
2008: Abraham B Schwarzberg; Cristina B Alexander; Daniel J DeAngelo; Simon M Helfgott
Clinical problem-solving. A joint venture.
The New England journal of medicine 2008;358(23):2496-501.
2008: Gregory A Abel; Daniel J DeAngelo; Jean M Connors; Lynette M Sholl; Ronald P McCaffrey; Janina A Longtine
Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations.
American journal of hematology 2008;83(6):519-20.
2008: Francis Giles; Daniel J DeAngelo; Michele Baccarani; Michael W N Deininger; françois guilhot; Timothy Hughes; Michael J Mauro; Jerald Radich; Oliver G Ottmann; Jorge Cortes
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Seminars in oncology 2008;35(1 Suppl 1):S1-17; quiz S18-20.
2007: Jennifer O'Neil; Joëlle Tchinda; Alejandro Gutierrez; Lisa A Moreau; richard s maser; Kwok-Kin Wong; Wei Li; Keith McKenna; Xiaole (Shirley) Liu; Bin Feng; Donna Neuberg; Lewis B Silverman; Daniel J DeAngelo; Jeffery L Kutok; Rodney Rothstein; Ronald A DePinho; Lynda Chin; Charles Lee; A Thomas Look
Alu elements mediate MYB gene tandem duplication in human T-ALL.
The Journal of experimental medicine 2007;204(13):3059-66.
2007: Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
Blood 2007;109(12):5136-42.
2007: Philippe Armand; Haesook T Kim; Daniel J DeAngelo; Vincent T Ho; Corey Cutler; Richard M Stone; Jerome Ritz; Edwin P Alyea; Joseph H Antin; Robert J Soiffer
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(6):655-64.
2007: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steven M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis Giles
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leukemia research 2007;31(5):599-604.
2007: Elly F Barry; Daniel J DeAngelo; Donna Neuberg; Kristen Stevenson; Mignon L Loh; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall Schorin; Harvey Jay Cohen; Stephen E Sallan; Lewis B Silverman
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):813-9.
2007: Ting Xi Liu; Michael W Becker; Jaroslav Jelinek; Wen-Shu Wu; Min Deng; Natallia Mikhalkevich; Karl Hsu; Clara D Bloomfield; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Jean-Pierre J Issa; Michael F Clarke; A Thomas Look
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Nature medicine 2007;13(1):78-83.
2006: Daniel J DeAngelo; Richard M Stone; Mark L Heaney; Stephen D Nimer; Ronald L Paquette; Rebecca B Klisovic; Michael A Caligiuri; Michael R Cooper; Jean-Michel Lecerf; Michael D Karol; Shihong Sheng; Nick Holford; Peter T Curtin; Brian J Druker; Michael C Heinrich
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Blood 2006;108(12):3674-81.
2006: Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Francis Giles; Elihu Estey; Andrew Lamb; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
2006: David A Barbie; Daniel J DeAngelo
Systemic mastocytosis: current classification and novel therapeutic options.
Clinical advances in hematology & oncology : H&O 2006;4(10):768-75.
2006: Edwin P Alyea; Haesook T Kim; Vincent T Ho; Corey Cutler; Daniel J DeAngelo; Richard M Stone; Jerome Ritz; Joseph H Antin; Robert J Soiffer
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(10):1047-55.
2006: Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross Levine
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
PLoS medicine 2006;3(7):e270.
2005: Kimberly Stegmaier; Steven M Corsello; Kenneth N Ross; Jenny S Wong; Daniel J DeAngelo; Todd R Golub
Gefitinib induces myeloid differentiation of acute myeloid leukemia.
Blood 2005;106(8):2841-8.
2005: Azra H Ligon; Daniel J DeAngelo; Leonard Atkins; Paola Dal Cin
Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies.
Cancer genetics and cytogenetics 2005;162(1):89-91.
2005: Xinping Yang; Liyun Liu; David W Sternberg; Liren Tang; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone
The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Cancer research 2005;65(16):7338-47.
2005: Nicole C Christacos; Leah Sherman; Alyssa Roy; Daniel J DeAngelo; Paola Dal Cin
Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome?
Cancer genetics and cytogenetics 2005;161(1):90-2.
2005: W Nicholas Haining; Angelo A Cardoso; Heather L Keczkemethy; Mark Fleming; Donna Neuberg; Daniel J DeAngelo; Richard M Stone; Ilene Galinsky; Lewis B Silverman; Stephen E Sallan; Lee M Nadler; Eva C Guinan
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
Experimental hematology 2005;33(3):286-94.
2005: Edwin P Alyea; Haesook T Kim; Vincent T Ho; Corey Cutler; John G Gribben; Daniel J DeAngelo; Stephanie J Lee; Sarah Windawi; Jerome Ritz; Richard M Stone; Joseph H Antin; Robert J Soiffer
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
Blood 2005;105(4):1810-4.
2005: Daniel J DeAngelo
The treatment of adolescents and young adults with acute lymphoblastic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():123-30.
2005: Daniel J DeAngelo
Review.
Clinical advances in hematology & oncology : H&O 2005;3(1):64-9.
2005: Ross Levine; Martha Wadleigh; David W Sternberg; Iwona Wlodarska; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; D Gary Gilliland; Jan Cools
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Leukemia 2005;19(1):27-30.
2005: Martha Wadleigh; Daniel J DeAngelo; James D Griffin; Richard M Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
Blood 2005;105(1):22-30.
2005: Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Elihu Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005;105(1):54-60.
2004: Jianlin Gong; Shigeo Koido; Yoko Kato; Yasuhiro Tanaka; Dongshu Chen; Anna Jonas; Ilene Galinsky; Daniel J DeAngelo; David Avigan; Donald Kufe; Richard M Stone
Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.
Leukemia research 2004;28(12):1303-12.
2004: Jing Chen; Daniel J DeAngelo; Jeffery L Kutok; Ifor Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian J P Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(40):14479-84.
2004: Jingrui Jiang; J Guillermo Paez; Jeffrey C Lee; Ronghai Bo; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Brian M Wolpin; Anna Jonasova; Paula Herman; Edward A Fox; Titus Boggon; Michael J Eck; Ellen Weisberg; James D Griffin; D Gary Gilliland; Matthew Meyerson; William R Sellers
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Blood 2004;104(6):1855-8.
2004: Daniel J DeAngelo; Ephraim P Hochberg; Edwin P Alyea; Janina Longtine; Stephanie Lee; Ilene Galinsky; Ben Parekkedon; Jerome Ritz; Joseph H Antin; Richard M Stone; Robert J Soiffer
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5065-71.
2004: Daniel J DeAngelo; Jerome Ritz
Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):1-3.
2003: Nancy U Lin; Stefanie Sarantopoulos; James R Stone; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Robert J Soiffer
Fatal hepatic necrosis following imatinib mesylate therapy.
Blood 2003;102(9):3455-6.
2003: Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Blood 2003;102(5):1578-82.
2003: Jan Cools; Elizabeth H Stover; Christina L Boulton; Jason Gotlib; Robert D Legare; Sonia M Amaral; David P Curley; Nicole Duclos; Rebecca Rowan; Jeffery L Kutok; Benjamin H Lee; Ifor Williams; Steven E Coutre; Richard M Stone; Daniel J DeAngelo; Peter Marynen; Paul W Manley; Thomas Meyer; Doriano Fabbro; Donna Neuberg; Ellen Weisberg; James D Griffin; D Gary Gilliland
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Cancer cell 2003;3(5):459-69.
2003: Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffery L Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Andrew Lamb; Peter Marynen; Steven E Coutre; Richard M Stone; D Gary Gilliland
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
The New England journal of medicine 2003;348(13):1201-14.
2003: John B Christoforidis; Daniel J DeAngelo; Donald J D'Amico
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
American journal of ophthalmology 2003;135(3):398-400.
2002: Catherine J Wu; Donna Neuberg; Antoinette Chillemi; Stephen McLaughlin; Ephraim P Hochberg; Ilene Galinsky; Daniel J DeAngelo; Robert J Soiffer; Edwin P Alyea; Renaud Capdeville; Richard M Stone; Jerome Ritz
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Leukemia & lymphoma 2002;43(12):2281-9.
2002: Edwin P Alyea; Edie Weller; David C Fisher; Arnold S Freedman; John G Gribben; Stephanie Lee; Robert Schlossman; Richard M Stone; Jonathan W Friedberg; Daniel J DeAngelo; Deborah Liney; Sarah Windawi; Andrea K Ng; Peter M Mauch; Joseph H Antin; Robert J Soiffer
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(11):601-7.
2001: D J Fowler; Daniel J DeAngelo; S Ariyanaygam; L Atkins
A new case of isolated del(12)(q15q22) in myelodysplastic syndrome.
Cancer genetics and cytogenetics 2001;130(1):89-91.
1998: pasha sarraf; Elisabetta Mueller; D Jones; F J King; Daniel J DeAngelo; J B Partridge; S A Holden; Lan Bo Chen; Samuel Singer; C Fletcher; Bruce M Spiegelman
Differentiation and reversal of malignant changes in colon cancer through PPARgamma.
Nature medicine 1998;4(9):1046-52.
1995: Daniel J DeAngelo; J DeFalco; L Rybacki; Geoffrey Childs
The embryonic enhancer-binding protein SSAP contains a novel DNA-binding domain which has homology to several RNA-binding proteins.
Molecular and cellular biology 1995;15(3):1254-64.
1993: Daniel J DeAngelo; J DeFalco; Geoffrey Childs
Purification and characterization of the stage-specific embryonic enhancer-binding protein SSAP-1.
Molecular and cellular biology 1993;13(3):1746-58.
1989: Z C Lai; Daniel J DeAngelo; M DiLiberto; Geoffrey Childs
An embryonic enhancer determines the temporal activation of a sea urchin late H1 gene.
Molecular and cellular biology 1989;9(6):2315-21.